Skip to content

US · RNXT · BIOTECHNOLOGY

RenovoRx, Inc. (RNXT) intrinsic value and stock valuation

$0.94as of 2026-11-21 · Mkt cap 39.46M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

RenovoRx, Inc. DCF and intrinsic value

InvestorsCraft values RNXT with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from RNXT’s statements →

RenovoRx, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Mountain View, CA 94040 renovorx.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$1.12M
20192025
Net income
-$-11.17M
20192025
Free cash flow
-$-10.97M
20192025
Total equity
$5.42M
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$1.12M$40K$0.00$0.00$0.00
Operating income-$-12.51M-$-10.97M-$-11.4M-$-9.95M-$-5.67M
Net income-$-11.17M-$-8.81M-$-10.23M-$-9.89M-$-6.32M
EPSd-$-316.16K-$-373.15K-$-497.08K-$-546.41K-$-353.67K
Operating cash flow-$-10.97M-$-9.12M-$-10.26M-$-8.81M-$-5.92M
Capital expenditure-$0.00-$-10K$0.00$0.00-$-10K
Free cash flow-$-10.97M-$-9.14M-$-10.26M-$-8.81M-$-5.93M
Total assets$8.1M$8.12M$1.47M$7.26M$16.3M
Total debt$210K$280K$0.00$0.00$0.00
Net debt-$-6.81M-$-6.88M-$-1.17M-$-4.39M-$-15.19M
Total equity$5.42M$4.48M-$-3M$6.16M$15.4M
Cash and short-term investments$7.02M$7.15M$1.17M$6.44M$15.2M
Income statement
20252024202320222021
Revenue$1.12M$40K$0.00$0.00$0.00
Cost of revenue$330K$0.00$0.00$0.00$0.00
Gross profit$800K$40K$0.00$0.00$0.00
Research and development expenses$6.27M$6.03M$5.67M$4.3M$3.04M
Selling, general and administrative expenses$7.04M$4.99M$5.73M$5.65M$2.63M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$13.3M$11M$11.4M$9.95M$5.67M
Cost and expenses$13.6M$11M$11.4M$9.95M$5.67M
Interest income$430K$380K$0.00$60K$70K
Interest expense$0.00$0.00$110K$60K$900K
Depreciation and amortization$0.00$0.00$10K$10K$10K
Ebitda-$-11.17M-$-8.81M-$-10.12M-$-9.83M-$-5.48M
Operating income-$-12.51M-$-10.97M-$-11.4M-$-9.95M-$-5.67M
Total other income/expenses, net$1.34M$2.16M$1.16M$60K-$-650K
Income before tax-$-11.17M-$-8.81M-$-10.23M-$-9.89M-$-6.32M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-11.17M-$-8.81M-$-10.23M-$-9.89M-$-6.32M
Weighted average shares outstanding$35.3M$23.6M$20.6M$18.1M$17.9M
Weighted average diluted shares outstanding$35.3M$23.6M$20.6M$18.1M$17.9M
Balance sheet
20252024202320222021
Cash and short-term investments$7.02M$7.15M$1.17M$6.44M$15.2M
Net receivables$140K$40K$0.00$0.00$0.00
Inventory$190K$0.00$0.00$0.00$0.00
Total current assets$7.89M$7.83M$1.47M$7.26M$16.3M
Property, plant and equipment, net$200K$290K$0.00$0.00$10K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$200K$290K$0.00$0.00$10K
Total assets$8.1M$8.12M$1.47M$7.26M$16.3M
Accounts payable$800K$590K$560K$530K$530K
Short-term debt$100K$70K$0.00$0.00$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$1.96M$1.91M$1.18M$1.1M$940K
Long-term debt$110K$210K$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$710K$1.73M$3.29M$0.00$0.00
Capital lease obligations$100K$280K$0.00$0.00$0.00
Total liabilities$2.67M$3.64M$4.47M$1.1M$940K
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-61.39M-$-50.22M-$-41.41M-$-31.17M-$-21.28M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$20K-$-16.29M
Total equity$5.42M$4.48M-$-3M$6.16M$15.4M
Total investments$0.00$0.00$0.00$2.05M$0.00
Total debt$210K$280K$0.00$0.00$0.00
Net debt-$-6.81M-$-6.88M-$-1.17M-$-4.39M-$-15.19M
Cash flow statement
20252024202320222021
Net income-$-11.17M-$-8.81M-$-10.23M-$-9.89M-$-6.32M
Depreciation and amortization$0.00$0.00$0.00$10K$10K
Stock-based compensation$1.27M$1.17M$1.08M$640K$150K
Change in working capital-$-250K$280K$600K$430K-$-270K
Accounts receivable-$-100K$0.00$0.00$0.00$0.00
Inventory-$-190K$0.00$0.00$0.00$0.00
Accounts payable$210K$30K$30K$10K$360K
Net cash provided by operating activities-$-10.97M-$-9.12M-$-10.26M-$-8.81M-$-5.92M
Investments in property, plant and equipment-$0.00-$-10K$0.00$0.00-$-10K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$0.00-$-10K$2.03M-$-2.03M-$-10K
Common stock issued$12.1M$15M$5M$40K$14.6M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$10.9M$15.1M$5.01M$40K$19.3M
Net change in cash-$-130K$5.98M-$-3.22M-$-10.8M$13.4M
Cash at end of period$7.02M$7.15M$1.17M$4.39M$15.2M
Operating cash flow-$-10.97M-$-9.12M-$-10.26M-$-8.81M-$-5.92M
Capital expenditure-$0.00-$-10K$0.00$0.00-$-10K
Free cash flow-$-10.97M-$-9.14M-$-10.26M-$-8.81M-$-5.93M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About RenovoRx, Inc.

        RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Established in 2009, RenovoRx, Inc. maintains its headquarters in Los Altos, California.

        CEO
        Shaun R. Bagai
        Employees
        17
        Beta
        0.99

        Explore

        Frequently asked questions

        What is the intrinsic value of RenovoRx, Inc. (RNXT)?

        InvestorsCraft does not currently publish an intrinsic value for RNXT. How the IC value is calculated.

        Is RNXT undervalued?

        InvestorsCraft does not publish an undervaluation signal for RNXT at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.